APVO (Aptevo Therapeutics) Buyback Yield % : -222.68 (As of Mar. 05, 2025)

View and export this data going back to 2016. Start your Free Trial

What is Aptevo Therapeutics Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Aptevo Therapeutics's current buyback yield was -222.68%.

Aptevo Therapeutics Buyback Yield % Historical Data

The historical data trend for Aptevo Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptevo Therapeutics Buyback Yield % Chart

Aptevo Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Buyback Yield %

Get a 7-Day Free Trial

-26.62

-45.90

-181.79

-159.71

Aptevo Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Buyback Yield %	Get a 7-Day Free Trial															-181.79	-154.50	-667.65	-289.55	-159.71

Competitive Comparison of Aptevo Therapeutics's Buyback Yield %

For the Biotechnology subindustry, Aptevo Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aptevo Therapeutics's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptevo Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Aptevo Therapeutics's Buyback Yield % falls into.

Aptevo Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Aptevo Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	10.036)	/	6.28398
	=	-159.71%

Aptevo Therapeutics's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(TTM)		/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	(TTM)^**	/	Market Cap
	=	- (0	+	10.036)		/	6.28398
	=	-159.71%

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Aptevo Therapeutics Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Aptevo Therapeutics's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptevo Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptevo Therapeutics Inc (NAS:APVO) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2401 4th Avenue, Suite 1050, Seattle, WA, USA, 98121

Website

https://www.aptevotherapeutics.com

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Executives

Daphne Taylor	officer: SVP, CFO	3303 MONTE VILLA PARKWAY, BOTHELL WA 98021
Kevin C Tang	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Soyoung Kwon	officer: See Remarks	APTEVO THERAPEUTICS INC., 2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Tang Capital Management Llc	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Randy Joe Maddux	officer: Senior VP, Operations	2401 4TH AVENUE, SUITE #1050, SEATTLE WA 98121
Fuad El-hibri	director	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Daniel Abdun-nabi	director	400 PROFESSIONAL DRIVE, SUITE 400, GAITHERSBURG MD 20879
Marvin L White	director, officer: President and CEO	2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Barbara Lopez Kunz	director	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Zsolt Harsanyi	director	2273 RESEARCH BLVD., SUITE 400, ROCKVILLE MD 20850
Grady Iii Grant	director	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Shawnte Mitchell	officer: SVP, GC and Corporate Affairs	5959 HORTON STREET, SUITE 500, EMERYVILLE CA 94608
Michael Adelman	officer: SVP, Commercial Operations	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Jane A Gross	officer: See Remarks	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121